Clinical Trials Center, Seoul National University Hospital
Seoul, South Korea
NCT Number: NCT01218347
This study aimed to explore the influence of organic anion transporting polypeptide1B1 (OATP1B1) genotype on pharmacokinetics, lipid lowering effect and lipid profiles after rosuvastatin administration.
Looking for future studies?
Notify Me20 year–50 year
All sexes
Interventional
Phase 4
Seoul, South Korea
Open, one arm, single sequence study for healthy volunteers are investigated. Thirty four subjects may be enrolled.
Rosuvastatin are administered once a day for 21 days. Before and after rosuvastatin administration, PK, PD and lipid profiles are investigated.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
20 mg once daily for 21 days
Time frame: Day 21 0h, 1h, 2h, 3h, 4h, 5h, 8h, 12h, 24h
Time frame: Day 1 0h, Day 22 0h
Time frame: Day -1 0h, Day21 0h, 4h, 8h
Seoul National University Hospital
Other
Influence of OATP1B1 Genotype on the Pharmacokinetics,Lipid Lowering Effect, and Lipid Profiles After Rosuvastatin Administration
Acronym: OATP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06910098
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
Lahore, Pakistan
View Trial DetailsNCT00228514
Cardiovascular Diseases, Heart Diseases
Groningen, Netherlands
View Trial Details